Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.40), $0.06 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• NewtekOne cuts EPS guidance, shifts focus to net interest income
• Benchmark Reiterates Buy Rating on Marvell (MRVL) Following Earnings